A citation-based method for searching scientific literature

Brooke E Howitt, Sachet A Shukla, Lynette M Sholl, Lauren L Ritterhouse, Jaclyn C Watkins, Scott Rodig, Elizabeth Stover, Kyle C Strickland, Alan D D'Andrea, Catherine J Wu, Ursula A Matulonis, Panagiotis A Konstantinopoulos. JAMA Oncol 2015
Times Cited: 397







List of co-cited articles
825 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Integrated genomic characterization of endometrial carcinoma.
Cyriac Kandoth, Nikolaus Schultz, Andrew D Cherniack, Rehan Akbani, Yuexin Liu, Hui Shen, A Gordon Robertson, Itai Pashtan, Ronglai Shen, Christopher C Benz,[...]. Nature 2013
49

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
37

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
35

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
936
31

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
Patrick A Ott, Yung-Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J Pishvaian, Hope S Rugo, Igor Puzanov, Janice M Mehnert, Kyaw L Aung, Juanita Lopez,[...]. J Clin Oncol 2017
258
20

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
Panagiotis A Konstantinopoulos, Weixiu Luo, Joyce F Liu, Doga C Gulhan, Carolyn Krasner, Jeffrey J Ishizuka, Allison A Gockley, Mary Buss, Whitfield B Growdon, Heather Crowe,[...]. J Clin Oncol 2019
90
20

A clinically applicable molecular-based classification for endometrial cancers.
A Talhouk, M K McConechy, S Leung, H H Li-Chang, J S Kwon, N Melnyk, W Yang, J Senz, N Boyd, A N Karnezis,[...]. Br J Cancer 2015
370
17

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Aline Talhouk, Melissa K McConechy, Samuel Leung, Winnie Yang, Amy Lum, Janine Senz, Niki Boyd, Judith Pike, Michael Anglesio, Janice S Kwon,[...]. Cancer 2017
331
17

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
16

Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.
S Kommoss, M K McConechy, F Kommoss, S Leung, A Bunz, J Magrill, H Britton, F Kommoss, F Grevenkamp, A Karnezis,[...]. Ann Oncol 2018
246
16

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Ellen Stelloo, Remi A Nout, Elisabeth M Osse, Ina J Jürgenliemk-Schulz, Jan J Jobsen, Ludy C Lutgens, Elzbieta M van der Steen-Banasik, Hans W Nijman, Hein Putter, Tjalling Bosse,[...]. Clin Cancer Res 2016
341
16

Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
Ana Oaknin, Anna V Tinker, Lucy Gilbert, Vanessa Samouëlian, Cara Mathews, Jubilee Brown, Maria-Pilar Barretina-Ginesta, Victor Moreno, Adriano Gravina, Cyril Abdeddaim,[...]. JAMA Oncol 2020
94
17

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Janice M Mehnert, Anshuman Panda, Hua Zhong, Kim Hirshfield, Sherri Damare, Katherine Lane, Levi Sokol, Mark N Stein, Lorna Rodriguez-Rodriquez, Howard L Kaufman,[...]. J Clin Invest 2016
258
15

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
Inge C van Gool, Florine A Eggink, Luke Freeman-Mills, Ellen Stelloo, Emanuele Marchi, Marco de Bruyn, Claire Palles, Remi A Nout, Cor D de Kroon, Elisabeth M Osse,[...]. Clin Cancer Res 2015
192
15

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Vicky Makker, Matthew H Taylor, Carol Aghajanian, Ana Oaknin, James Mier, Allen L Cohn, Margarita Romeo, Raquel Bratos, Marcia S Brose, Christopher DiSimone,[...]. J Clin Oncol 2020
210
15

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
15

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Hyun Cheol Chung, Willeke Ros, Jean-Pierre Delord, Ruth Perets, Antoine Italiano, Ronnie Shapira-Frommer, Lyudmila Manzuk, Sarina A Piha-Paul, Lei Xu, Susan Zeigenfuss,[...]. J Clin Oncol 2019
400
14

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
13

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti,[...]. Int J Gynecol Cancer 2021
327
13

Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.
Aline Talhouk, Heather Derocher, Pascal Schmidt, Samuel Leung, Katy Milne, C Blake Gilks, Michael S Anglesio, Brad H Nelson, Jessica N McAlpine. Clin Cancer Res 2019
64
20


Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
12

Interpretation of somatic POLE mutations in endometrial carcinoma.
Alicia León-Castillo, Heidi Britton, Melissa K McConechy, Jessica N McAlpine, Remi Nout, Stefan Kommoss, Sara Y Brucker, Joseph W Carlson, Elisabeth Epstein, Tilman T Rau,[...]. J Pathol 2020
103
12

Prognostic significance of POLE proofreading mutations in endometrial cancer.
David N Church, Ellen Stelloo, Remi A Nout, Nadejda Valtcheva, Jeroen Depreeuw, Natalja ter Haar, Aurelia Noske, Frederic Amant, Ian P M Tomlinson, Peter J Wild,[...]. J Natl Cancer Inst 2014
188
12

DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
David N Church, Sarah E W Briggs, Claire Palles, Enric Domingo, Stephen J Kearsey, Jonathon M Grimes, Maggie Gorman, Lynn Martin, Kimberley M Howarth, Shirley V Hodgson,[...]. Hum Mol Genet 2013
231
12

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.
Feng Wang, Qi Zhao, Ying-Nan Wang, Ying Jin, Ming-Ming He, Ze-Xian Liu, Rui-Hua Xu. JAMA Oncol 2019
176
12

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Vicky Makker, Drew Rasco, Nicholas J Vogelzang, Marcia S Brose, Allen L Cohn, James Mier, Christopher Di Simone, David M Hyman, Daniel E Stepan, Corina E Dutcus,[...]. Lancet Oncol 2019
266
11


Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma.
C Blake Gilks, Esther Oliva, Robert A Soslow. Am J Surg Pathol 2013
220
11

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
Alicia León-Castillo, Stephanie M de Boer, Melanie E Powell, Linda R Mileshkin, Helen J Mackay, Alexandra Leary, Hans W Nijman, Naveena Singh, Pamela M Pollock, Paul Bessette,[...]. J Clin Oncol 2020
177
11

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
699
11

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
10

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Tjalling Bosse, Remi A Nout, Jessica N McAlpine, Melissa K McConechy, Heidi Britton, Yaser R Hussein, Carlene Gonzalez, Raji Ganesan, Jane C Steele, Beth T Harrison,[...]. Am J Surg Pathol 2018
130
10

Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho,[...]. N Engl J Med 2014
10


A panoply of errors: polymerase proofreading domain mutations in cancer.
Emily Rayner, Inge C van Gool, Claire Palles, Stephen E Kearsey, Tjalling Bosse, Ian Tomlinson, David N Church. Nat Rev Cancer 2016
211
10

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Enric Domingo, Luke Freeman-Mills, Emily Rayner, Mark Glaire, Sarah Briggs, Louis Vermeulen, Evelyn Fessler, Jan Paul Medema, Arnoud Boot, Hans Morreau,[...]. Lancet Gastroenterol Hepatol 2016
164
10

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
10

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, David Fabrizio, Laurie Gay, Siraj M Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki,[...]. Genome Med 2017
9

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee. N Engl J Med 2017
9

PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Annukka Pasanen, Terhi Ahvenainen, Teijo Pellinen, Pia Vahteristo, Mikko Loukovaara, Ralf Bützow. Am J Surg Pathol 2020
37
24

Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
Alicia León-Castillo, Ester Gilvazquez, Remi Nout, Vincent Thbm Smit, Jessica N McAlpine, Melissa McConechy, Stefan Kommoss, Sara Y Brucker, Joseph W Carlson, Elisabeth Epstein,[...]. J Pathol 2020
106
9

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.
Florine A Eggink, Inge C Van Gool, Alexandra Leary, Pamela M Pollock, Emma J Crosbie, Linda Mileshkin, Ekaterina S Jordanova, Julien Adam, Luke Freeman-Mills, David N Church,[...]. Oncoimmunology 2016
76
11

Endometrial cancer.
Philippe Morice, Alexandra Leary, Carien Creutzberg, Nadeem Abu-Rustum, Emile Darai. Lancet 2016
868
9

Comprehensive Analysis of Hypermutation in Human Cancer.
Brittany B Campbell, Nicholas Light, David Fabrizio, Matthew Zatzman, Fabio Fuligni, Richard de Borja, Scott Davidson, Melissa Edwards, Julia A Elvin, Karl P Hodel,[...]. Cell 2017
440
9

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Ellen Stelloo, Tjalling Bosse, Remi A Nout, Helen J MacKay, David N Church, Hans W Nijman, Alexandra Leary, Richard J Edmondson, Melanie E Powell, Emma J Crosbie,[...]. Mod Pathol 2015
248
9


PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
9

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Daniel Temko, Inge C Van Gool, Emily Rayner, Mark Glaire, Seiko Makino, Matthew Brown, Laura Chegwidden, Claire Palles, Jeroen Depreeuw, Andrew Beggs,[...]. J Pathol 2018
54
16

Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
Anne M Mills, Sofia Liou, James M Ford, Jonathan S Berek, Reetesh K Pai, Teri A Longacre. Am J Surg Pathol 2014
154
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.